Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
64 Total results for product and free and sample content found
Trialtrove, Pharmaprojects
By Ethan Hebert 13 Jul 2018
In the following, I will leverage Trialtrove and Pharmaprojects data to assess 2017 trial initiations focused on non-alcoholic fatty liver disease (NAFLD), including the subtype non-alcoholic steatohepatitis (NASH). This analysis will include an initial wide glance at the trial landscape, focusing down to industry-sponsored trials in NASH.
Topic Diseases
Trialtrove
By Susan Danheiser 09 Jul 2018
The timing of when sponsors report clinical trials in the public domain continues to be a topic of interest. Despite efforts to regulate and encourage prospective reporting of study starts, delayed reporting remains and is a factor that is often overlooked when evaluating clinical trial trends. Here, we examine the magnitude of clinical trial reporting delays and how they can be accounted for in your analyses.
Topic Clinical trials
Trialtrove
By Citeline Oncology Editorial Team 15 Jun 2018
In oncology trials, patients are often differentiated based on line of therapy (LOT) for their current disease stage. Briefly, patients can be naïve/untreated (First line), treated before or after surgery/radiation (Neoadjuvant and Adjuvant), treated after progressing on a previous line of therapy (Second line or greater) or treated to maintain a positive response (Maintenance/Consolidation). In Trialtrove, these LOT patient segments have been applied to most oncological disease trials for almost a decade.
Topic Cancer
Trialtrove
By Jake Mathon 08 Jun 2018
It has long been known that diabetes is a risk factor for heart failure. Analysis from the Framingham Heart Study established that men with type 2 diabetes had a 2.4-fold increase in heart failure and women had a five-fold increase. This link between the diseases is not just one way as more recent research has found the reverse to be in effect as well, that heart failure indeed is its own risk factor for diabetes mellitus.
Topic Diabetes
Datamonitor Healthcare
24 May 2018
Phase III MIST trial data presented at the 2018 annual meeting of the American Academy of Neurology (AAN) highlight autologous hematopoietic stem cell therapy (aHSCT) as a radically novel prospect for multiple sclerosis (MS) treatment, with an unprecedented curative potential. Certainly, aHSCT’s potential to reverse disability is markedly distinct from currently available disease-modifying therapies (DMTs), which can only slow disability progression.
Trialtrove
By Laurie Withington 09 May 2018
The wearable technology market is rapidly growing, and impacting many different areas of our culture such as social interaction, entertainment, environment, self-awareness, and healthcare. Techcrunch has forecasted sales of wearable devices worldwide this year at $30.5BN in total revenue . As more money is spent on wearable devices, innovation expands, which in turn increases the many facets of our lives that these devices can be incorporated into.
Topic Clinical trials
Pharmaprojects
By Pippa Nutkins 18 Apr 2018
After our review of the drug development landscape for eating disorders, we investigated the latest research trends and pharmacological interventions for the escalating global obesity epidemic. The argument that eating disorders and obesity are similarly manifested in genetic, metabolic and psychological origins could be an important consideration for drug development in these two complex indications. Are such similarities reflected in the drug development pipelines and what are the prospects for these multifactorial diseases?
Pharmaprojects
By Pippa Nutkins 02 Mar 2018
We investigated the latest research trends and pharmacological interventions for the escalating global obesity epidemic. The argument that eating disorders and obesity are similarly manifested in genetic, metabolic and psychological origins could be an important consideration for drug development in these two complex indications.
Pharmaprojects, Trialtrove
By Judy Adair 28 Feb 2018
February 28, 2018 is the eleventh international #Rare Disease Day. This day is designed to raise awareness about rare diseases and their impact on patient’s lives to public and decision-makers in government and health fields. Scrutiny of rare diseases is vital as there are approximately 7,000 different types of rare diseases and approximately 80 percent are caused by faulty genes [1]. This paper will focus on one, Huntington’s Disease (HD).
Topic Rare Disease
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
